Leukaemia Section

Short Communication

**t(1;3)(p36;q21)**

Jean-Loup Huret

Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France

Published in Atlas Database: August 1997

Online version is available at: http://AtlasGeneticsOncology.org/Anomalies/t0103.html

DOI: 10.4267/2042/32028

This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence.

© 1997 Atlas of Genetics and Cytogenetics in Oncology and Haematology

**Clinics and pathology**

**Disease**

Myeloid lineage (MDS, ANLL, therapy related ANLL, BC-CML)

**Phenotype / cell stem origin**

MDS (RA: 3 cases; RAEB: 4 cases; CMML: 2 cases; RAEBT: 1 case); ANLL (M1, M4...), often (13/16 cases) with preceding MDS, according to cases herein reviewed; seem to involve a myeloid stem cell, t(1;3) being absent from B or T lymphocytes; may be secondary to toxic exposure.

**Epidemiology**

Median age: 49 yrs; sex ratio: 7M/9F.

**Clinics**

Blood data: frequent thrombocytosis.

**Cytology**

Dysmegakaryocytopoiesis.

**Prognosis**

Very poor so far: median survival is 6 mths in ANLL, 20 mths in MDS.

**Cytogenetics**

**Additional anomalies**

del (5q) in 3 of 16 cases.

**To be noted**

This translocation share commun features with inv(3)(q21q26), t(3;3)(q21;q26), and t(3;5)(q21-25;q31-35).

**References**


*This article should be referenced as such:*